{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:41:02Z","timestamp":1788579662365,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201500010C"],"award-info":[{"award-number":["HHSO100201500010C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2018.01.050","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T17:43:12Z","timestamp":1517506992000},"page":"1146-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Influenza B virus reverse genetic backbones with improved growth properties in the EB66\u00ae cell line as basis for vaccine seed virus generation"],"prefix":"10.1016","volume":"36","author":[{"given":"Kris M.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ayllon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Potenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.050_b0005","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.050_b0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.01.050_b0015","doi-asserted-by":"crossref","first-page":"15314","DOI":"10.1038\/srep15314","article-title":"The role of influenza in the epidemiology of pneumonia","volume":"5","author":"Shrestha","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.01.050_b0020","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/S0140-6736(06)69895-4","article-title":"Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918\u201320 pandemic: a quantitative analysis","volume":"368","author":"Murray","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.01.050_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 Influenza: the mother of all pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.050_b0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3201\/eid1802.102042","article-title":"Pathogenic responses among young adults during the 1918 influenza pandemic","volume":"18","author":"Shanks","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.050_b0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2010.11.042","article-title":"Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective","volume":"29","author":"Abelin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.050_b0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra1208802","article-title":"Pandemic preparedness and response\u2013lessons from the H1N1 influenza of 2009","volume":"370","author":"Fineberg","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.050_b0045","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1016\/j.vaccine.2017.04.065","article-title":"Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics","volume":"35","author":"Milian","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.050_b0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.01.050_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.8.1.18859","article-title":"New technologies for influenza vaccines","volume":"8","author":"Dormitzer","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.01.050_b0060","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200868110-00002","article-title":"Cell-based influenza vaccines: progress to date","volume":"68","author":"Audsley","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.01.050_b0065","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/erv.12.55","article-title":"Preflucel(R): a Vero-cell culture-derived trivalent influenza vaccine","volume":"11","author":"Chan","year":"2012","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.01.050_b0070","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","article-title":"FluBlok, a next generation influenza vaccine manufactured in insect cells","volume":"37","author":"Cox","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2018.01.050_b0075","first-page":"419","article-title":"The avian EB66(R) cell line, application to vaccines, and therapeutic protein production","volume":"64","author":"Brown","year":"2010","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.vaccine.2018.01.050_b0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/infdis\/jiv091","article-title":"Immunogenicity and safety of an EB66 cell-culture-derived influenza A\/Indonesia\/5\/2005(H5N1) AS03-Adjuvanted vaccine: a phase 1 randomized trial","volume":"212","author":"Schuind","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.050_b0085","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1016\/j.vaccine.2015.09.022","article-title":"A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03","volume":"33","author":"Naruse","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.050_b0090","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1016\/j.vaccine.2016.10.043","article-title":"The EB66(R) cell line as a valuable cell substrate for MVA-based vaccines production","volume":"34","author":"Leon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.050_b0095","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2015.06.110","article-title":"Cell substrates for the production of viral vaccines","volume":"33","author":"Aubrit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.050_b0100","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1038\/ncomms9148","article-title":"Development of high-yield influenza A virus vaccine viruses","volume":"6","author":"Ping","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.01.050_b0105","doi-asserted-by":"crossref","first-page":"15940","DOI":"10.1038\/srep15940","article-title":"Mouse adaptation of influenza B virus increases replication in the upper respiratory tract and results in droplet transmissibility in ferrets","volume":"5","author":"Kim","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.01.050_b0110","doi-asserted-by":"crossref","first-page":"e1003150","DOI":"10.1371\/journal.ppat.1003150","article-title":"Human monoclonal antibodies broadly neutralizing against influenza B virus","volume":"9","author":"Yasugi","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.01.050_b0115","doi-asserted-by":"crossref","DOI":"10.3791\/2057","article-title":"Generation of recombinant influenza virus from plasmid DNA","author":"Martinez-Sobrido","year":"2010","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2018.01.050_b0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/adb.12305","article-title":"Methadone enhances human influenza A virus replication","volume":"22","author":"Chen","year":"2017","journal-title":"Addict Biol"},{"key":"10.1016\/j.vaccine.2018.01.050_b0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.antiviral.2008.05.008","article-title":"Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity","volume":"80","author":"Hoffmann","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.01.050_b0130","doi-asserted-by":"crossref","first-page":"E8296","DOI":"10.1073\/pnas.1616530113","article-title":"Development of high-yield influenza B virus vaccine viruses","volume":"113","author":"Ping","year":"2016","journal-title":"Proc Natl Acad Sci (USA)"},{"issue":"22","key":"10.1016\/j.vaccine.2018.01.050_b0135","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1056\/NEJMp1005102","article-title":"The public's response to the 2009 H1N1 influenza pandemic","volume":"362","author":"SteelFisher","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.050_b0140","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/bit.22753","article-title":"Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process","volume":"106","author":"George","year":"2010","journal-title":"Biotechnol Bioeng"},{"issue":"44","key":"10.1016\/j.vaccine.2018.01.050_b0145","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1016\/j.vaccine.2010.08.059","article-title":"Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor","volume":"28","author":"Chu","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:27Z","timestamp":1759400667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18300999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X18300999"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influenza B virus reverse genetic backbones with improved growth properties in the EB66\u00ae cell line as basis for vaccine seed virus generation","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}